An improved method for the determination of islet amyloid polypeptide levels in plasma

K. L. Van Hulst, W. H.L. Hackeng, J. W.M. Höppener, B. C. Van Jaarsveld, M. G. Nieuwenhuis, M. A. Blankenstein, C. J.M. Lips

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

We describe an improved method for the determination of islet amyloid polypeptide (IAPP) levels in plasma. Plasma is first extracted with acid-acetone, followed by a specific and sensitive radioimmunoassay (RIA) for IAPP using rabbit-anti-human-IAPP serum. Recovery of synthetic IAPP from plasma was 82±6% (n = 16). Standard samples, prepared in ‘hormone-free’ serum, were also extracted with acid-acetone. Displacement curves of serially diluted acid-acetone extracted plasma samples were parallel to the standard curve. The lower detection limit of the RIA was 2·3 ± 0·1 fmol/sample (n = 5). Intra-assay variations for IAPP concentrations of 4, 17 and 32 pM were 16·3% (n = 10), 9·2% (n = 10) and 6·2% (n = 10); inter-assay variations were 35·9% (n = 14), 19·9% (n = 15) and 15·4% (n = 15), respectively. Non-stimulated IAPP levels ranged from 2·4 to 12 pM (mean 6±4pM, n = 10) in healthy control subjects. IAPP was not detectable in type 1 (insulin-dependent) diabetic patients before and after glucagon administration. In type 2 (non-insulin-dependent) diabetic patients basal levels ranged from 2·2 to 14·5 pM and glucagon-stimulated levels ranged from 2·2 to 38·9 pM. The increase in IAPP varied from 0 to 24·4 pM. The anti-human-IAPP serum had full cross-reactivity with rat IAPP (= mouse IAPP). Transgenic mice overexpressing the human IAPP gene showed elevated plasma IAPP levels as compared to (non-transgenic) control mice. It is concluded that the method presented for the determination of IAPP in plasma is reliable and easy to perform, yielding reproducible results. The ability to measure plasma IAPP levels will help to elucidate the physiological function of IAPP as well as its pathophysiological role in type 2 diabetes mellitus.

Original languageEnglish
Pages (from-to)165-170
Number of pages6
JournalAnnals of Clinical Biochemistry
Volume31
Issue number2
DOIs
Publication statusPublished - 1 Jan 1994

Cite this

Van Hulst, K. L. ; Hackeng, W. H.L. ; Höppener, J. W.M. ; Van Jaarsveld, B. C. ; Nieuwenhuis, M. G. ; Blankenstein, M. A. ; Lips, C. J.M. / An improved method for the determination of islet amyloid polypeptide levels in plasma. In: Annals of Clinical Biochemistry. 1994 ; Vol. 31, No. 2. pp. 165-170.
@article{e8fadfca7d354e58a2707229e44dfc7f,
title = "An improved method for the determination of islet amyloid polypeptide levels in plasma",
abstract = "We describe an improved method for the determination of islet amyloid polypeptide (IAPP) levels in plasma. Plasma is first extracted with acid-acetone, followed by a specific and sensitive radioimmunoassay (RIA) for IAPP using rabbit-anti-human-IAPP serum. Recovery of synthetic IAPP from plasma was 82±6{\%} (n = 16). Standard samples, prepared in ‘hormone-free’ serum, were also extracted with acid-acetone. Displacement curves of serially diluted acid-acetone extracted plasma samples were parallel to the standard curve. The lower detection limit of the RIA was 2·3 ± 0·1 fmol/sample (n = 5). Intra-assay variations for IAPP concentrations of 4, 17 and 32 pM were 16·3{\%} (n = 10), 9·2{\%} (n = 10) and 6·2{\%} (n = 10); inter-assay variations were 35·9{\%} (n = 14), 19·9{\%} (n = 15) and 15·4{\%} (n = 15), respectively. Non-stimulated IAPP levels ranged from 2·4 to 12 pM (mean 6±4pM, n = 10) in healthy control subjects. IAPP was not detectable in type 1 (insulin-dependent) diabetic patients before and after glucagon administration. In type 2 (non-insulin-dependent) diabetic patients basal levels ranged from 2·2 to 14·5 pM and glucagon-stimulated levels ranged from 2·2 to 38·9 pM. The increase in IAPP varied from 0 to 24·4 pM. The anti-human-IAPP serum had full cross-reactivity with rat IAPP (= mouse IAPP). Transgenic mice overexpressing the human IAPP gene showed elevated plasma IAPP levels as compared to (non-transgenic) control mice. It is concluded that the method presented for the determination of IAPP in plasma is reliable and easy to perform, yielding reproducible results. The ability to measure plasma IAPP levels will help to elucidate the physiological function of IAPP as well as its pathophysiological role in type 2 diabetes mellitus.",
keywords = "amylin, diabetes mellitus, glucagon stimulation, islet amyloid polypeptide, radioimmunoassay",
author = "{Van Hulst}, {K. L.} and Hackeng, {W. H.L.} and H{\"o}ppener, {J. W.M.} and {Van Jaarsveld}, {B. C.} and Nieuwenhuis, {M. G.} and Blankenstein, {M. A.} and Lips, {C. J.M.}",
year = "1994",
month = "1",
day = "1",
doi = "10.1177/000456329403100209",
language = "English",
volume = "31",
pages = "165--170",
journal = "Annals of Clinical Biochemistry",
issn = "0004-5632",
publisher = "SAGE Publications Ltd",
number = "2",

}

An improved method for the determination of islet amyloid polypeptide levels in plasma. / Van Hulst, K. L.; Hackeng, W. H.L.; Höppener, J. W.M.; Van Jaarsveld, B. C.; Nieuwenhuis, M. G.; Blankenstein, M. A.; Lips, C. J.M.

In: Annals of Clinical Biochemistry, Vol. 31, No. 2, 01.01.1994, p. 165-170.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - An improved method for the determination of islet amyloid polypeptide levels in plasma

AU - Van Hulst, K. L.

AU - Hackeng, W. H.L.

AU - Höppener, J. W.M.

AU - Van Jaarsveld, B. C.

AU - Nieuwenhuis, M. G.

AU - Blankenstein, M. A.

AU - Lips, C. J.M.

PY - 1994/1/1

Y1 - 1994/1/1

N2 - We describe an improved method for the determination of islet amyloid polypeptide (IAPP) levels in plasma. Plasma is first extracted with acid-acetone, followed by a specific and sensitive radioimmunoassay (RIA) for IAPP using rabbit-anti-human-IAPP serum. Recovery of synthetic IAPP from plasma was 82±6% (n = 16). Standard samples, prepared in ‘hormone-free’ serum, were also extracted with acid-acetone. Displacement curves of serially diluted acid-acetone extracted plasma samples were parallel to the standard curve. The lower detection limit of the RIA was 2·3 ± 0·1 fmol/sample (n = 5). Intra-assay variations for IAPP concentrations of 4, 17 and 32 pM were 16·3% (n = 10), 9·2% (n = 10) and 6·2% (n = 10); inter-assay variations were 35·9% (n = 14), 19·9% (n = 15) and 15·4% (n = 15), respectively. Non-stimulated IAPP levels ranged from 2·4 to 12 pM (mean 6±4pM, n = 10) in healthy control subjects. IAPP was not detectable in type 1 (insulin-dependent) diabetic patients before and after glucagon administration. In type 2 (non-insulin-dependent) diabetic patients basal levels ranged from 2·2 to 14·5 pM and glucagon-stimulated levels ranged from 2·2 to 38·9 pM. The increase in IAPP varied from 0 to 24·4 pM. The anti-human-IAPP serum had full cross-reactivity with rat IAPP (= mouse IAPP). Transgenic mice overexpressing the human IAPP gene showed elevated plasma IAPP levels as compared to (non-transgenic) control mice. It is concluded that the method presented for the determination of IAPP in plasma is reliable and easy to perform, yielding reproducible results. The ability to measure plasma IAPP levels will help to elucidate the physiological function of IAPP as well as its pathophysiological role in type 2 diabetes mellitus.

AB - We describe an improved method for the determination of islet amyloid polypeptide (IAPP) levels in plasma. Plasma is first extracted with acid-acetone, followed by a specific and sensitive radioimmunoassay (RIA) for IAPP using rabbit-anti-human-IAPP serum. Recovery of synthetic IAPP from plasma was 82±6% (n = 16). Standard samples, prepared in ‘hormone-free’ serum, were also extracted with acid-acetone. Displacement curves of serially diluted acid-acetone extracted plasma samples were parallel to the standard curve. The lower detection limit of the RIA was 2·3 ± 0·1 fmol/sample (n = 5). Intra-assay variations for IAPP concentrations of 4, 17 and 32 pM were 16·3% (n = 10), 9·2% (n = 10) and 6·2% (n = 10); inter-assay variations were 35·9% (n = 14), 19·9% (n = 15) and 15·4% (n = 15), respectively. Non-stimulated IAPP levels ranged from 2·4 to 12 pM (mean 6±4pM, n = 10) in healthy control subjects. IAPP was not detectable in type 1 (insulin-dependent) diabetic patients before and after glucagon administration. In type 2 (non-insulin-dependent) diabetic patients basal levels ranged from 2·2 to 14·5 pM and glucagon-stimulated levels ranged from 2·2 to 38·9 pM. The increase in IAPP varied from 0 to 24·4 pM. The anti-human-IAPP serum had full cross-reactivity with rat IAPP (= mouse IAPP). Transgenic mice overexpressing the human IAPP gene showed elevated plasma IAPP levels as compared to (non-transgenic) control mice. It is concluded that the method presented for the determination of IAPP in plasma is reliable and easy to perform, yielding reproducible results. The ability to measure plasma IAPP levels will help to elucidate the physiological function of IAPP as well as its pathophysiological role in type 2 diabetes mellitus.

KW - amylin

KW - diabetes mellitus

KW - glucagon stimulation

KW - islet amyloid polypeptide

KW - radioimmunoassay

UR - http://www.scopus.com/inward/record.url?scp=0028266730&partnerID=8YFLogxK

U2 - 10.1177/000456329403100209

DO - 10.1177/000456329403100209

M3 - Article

VL - 31

SP - 165

EP - 170

JO - Annals of Clinical Biochemistry

JF - Annals of Clinical Biochemistry

SN - 0004-5632

IS - 2

ER -